In: NEOPLASMA, vol. 57, no. 1
J Minarik - V Scudla - J Bacovsky - M Zemanova - T Pika - M Ordeltova - K Langova
Detaily:
Rok, strany: 2010, 8 - 14
O článku:
We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI ven after 40 months (median overall survival 25 vs 10months, p = 0.015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in all MM patients. Keywords: myeloma – prognostication – proliferative index – biological therapy
Ako citovať:
ISO 690:
Minarik, J., Scudla, V., Bacovsky, J., Zemanova, M., Pika, T., Ordeltova, M., Langova, K. 2010. Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma. In NEOPLASMA, vol. 57, no.1, pp. 8-14. 0028-2685.
APA:
Minarik, J., Scudla, V., Bacovsky, J., Zemanova, M., Pika, T., Ordeltova, M., Langova, K. (2010). Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma. NEOPLASMA, 57(1), 8-14. 0028-2685.